|Bid||77.00 x 700|
|Ask||81.89 x 300|
|Day's Range||80.53 - 81.75|
|52 Week Range||78.42 - 102.06|
|PE Ratio (TTM)||-24.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Evercore ISI analyst Josh Schimmer is bullish on biotech.
Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.72 billion.